Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_3
1
25%
Ph phase_2
1
25%
Ph phase_4
2
50%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 42 (50.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

NCT00074581
completedphase_2

Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial

NCT00272480
completedphase_4

Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada

NCT00324649
completedphase_4

Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting

NCT01772940

Clinical Trials (4)

Showing 4 of 4 trials
NCT00074581Phase 3

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Completed
NCT00272480Phase 2

Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial

Completed
NCT00324649Phase 4

Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada

Completed
NCT01772940Phase 4

Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4